Zacks Research Upgrades NextCure (NASDAQ:NXTC) to Hold

NextCure (NASDAQ:NXTC) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research note on Monday, April 27th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $23.00.

NextCure Price Performance

NXTC opened at $2.08 on Thursday. The business’s 50-day moving average is $8.56 and its two-hundred day moving average is $11.00. NextCure has a 1 year low of $2.00 and a 1 year high of $15.74. The firm has a market capitalization of $7.51 million, a PE ratio of -0.12 and a beta of 1.30.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.10) by $0.23. As a group, sell-side analysts expect that NextCure will post -7.9 EPS for the current year.

Hedge Funds Weigh In On NextCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in NXTC. Cable Car Capital LP grew its stake in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares during the last quarter. Geode Capital Management LLC boosted its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares in the last quarter. Exome Asset Management LLC acquired a new stake in NextCure in the fourth quarter worth about $2,341,000. Finally, AWM Investment Company Inc. acquired a new stake in NextCure in the fourth quarter worth about $1,665,000. Hedge funds and other institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.